Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)
July 12 2018 - 10:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F/A
Amendment No. 1
|
¨
|
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
OR
|
þ
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the Fiscal Year Ended March 31, 2018
OR
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
OR
|
¨
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
Commission File Number: 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Exact name of Registrant as specified
in its charter)
Not Applicable
|
TELANGANA, INDIA
|
(Translation of Registrant’s name
|
(Jurisdiction of incorporation or
|
into English)
|
organization)
|
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive offices)
Saumen Chakraborty,
Chief Financial Officer,
+91-40-49002004, saumenc@drreddys.com
8-2-337, Road No. 3, Banjara Hills, Hyderabad,
Telangana 500 034, India
(Name, telephone, e-mail and/or facsimile number
and address of company contact person)
Securities registered or to be registered pursuant
to Section 12(b) of the Act.
Title of Each Class
|
|
Name of Each Exchange on which Registered
|
American depositary shares, each
|
|
New York Stock Exchange
|
representing one equity share
|
|
|
Equity Shares*
|
*
|
Not for trading, but only in connection with the registration
of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission
.
|
Securities registered or to be
registered pursuant to Section 12(g) of the Act. None.
Securities for which there is a reporting obligation pursuant to
Section 15(d) of the Act. None.
Indicate the number of outstanding shares of each of the issuer’s
classes of capital or common stock as of the close of the period covered by the annual report.
165,910,907 Equity Shares
Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.
Yes
þ
No
¨
If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934.
Yes
¨
No
þ
Note — Checking the box above will not
relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their
obligations under those Sections.
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes
þ
No
¨
Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files).
Yes
þ
No
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See the definitions
of “accelerated filer”, “large accelerated filer” and “emerging growth company” in Rule 12b-2
of the Exchange Act. (Check one):
Large accelerated filer
þ
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Emerging growth company
¨
|
If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards†
provided pursuant to Section 13(a) of the Exchange Act.
¨
† The term “new or revised financial
accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards
Codification after April 5, 2012.
Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP
¨
|
International Financial Reporting Standards as issued
þ
|
Other
¨
|
|
by the International Accounting Standards Board
|
|
If “Other” has been checked in
response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
Item
17
¨
Item 18
¨
If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).
Yes
¨
No
þ
Explanatory Note
This
Amendment No. 1 to the Annual Report on Form 20-F of Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”)
amends its Annual Report on Form 20-F for the year ended March 31, 2018, which was filed with the Securities and
Exchange Commission on June 15, 2018. Dr. Reddy’s is filing this Amendment No. 1 solely to furnish the Interactive
Data File discloser as Exhibit 101 in accordance with Rule 405 of Regulation S-T, which was omitted from the Form 20-F in accordance
with the 30-day grace period provided
under Rule 405(a)(2)(ii) of Regulation S-T
. Exhibit 101
includes information in eXtensible Business Reporting Language (“XBRL”).
Except
as described above, this Amendment No. 1 does not amend any information set forth in the Original 20-F, and Dr.
Reddy’s has not updated disclosures included therein to reflect any events that may have occurred subsequent to June 15, 2018.
ITEM 19. EXHIBITS
(1)
In accordance with Rule 402
of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of
the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
SIGNATURE
The registrant hereby certifies that it meets
all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment
No. 1 to the Annual Report on Form 20-F on its behalf.
Hyderabad, India
|
/s/ Saumen Chakraborty
|
|
Saumen Chakraborty
|
Date: July 12, 2018
|
President and Chief Financial Officer
|
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2024 to May 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2023 to May 2024